Sattva Neelapu
Overview
Explore the profile of Sattva Neelapu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
2289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walder J, Soto-Lanza F, Feng L, Ahmed S, Neelapu S, Ayers A, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 40000355
Background: Chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment of certain hematologic malignancies, but toxicities limit efficacy. The role of pre-CAR-T pulmonary function testing (PFT) to predict toxicities...
2.
Fang P, Noticewala S, Wu S, Gunther J, Ludmir E, Medeiros L, et al.
Adv Radiat Oncol
. 2024 Nov;
9(12):101650.
PMID: 39553398
Purpose: Extranodal NK/T-cell lymphoma (ENKTCL) is rare in the Western Hemisphere and is commonly treated with combined modality therapy (CMT). Methods And Materials: We retrospectively reviewed 35 patients treated with...
3.
Szymura S, Wang L, Zhang T, Cha S, Song J, Dong Z, et al.
Nat Commun
. 2024 Aug;
15(1):6874.
PMID: 39128904
Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade lymphoma with no standard therapy. Nine asymptomatic patients treated with a first-in-human, neoantigen DNA vaccine experienced no dose limiting toxicities (primary endpoint, NCT01209871)....
4.
Pinnix C, Dabaja B, Gunther J, Fang P, Wu S, Nastoupil L, et al.
JAMA Oncol
. 2024 Jul;
10(9):1195-1203.
PMID: 38990564
Importance: Radiation therapy to doses of 24 to 36 Gy is currently used to treat indolent B-cell lymphoma of the ocular adnexa; however, ocular adverse effects are common. Objective: To...
5.
Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua M, An X, et al.
Nat Cancer
. 2024 May;
5(6):954.
PMID: 38778179
No abstract available.
6.
Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua M, An X, et al.
Nat Cancer
. 2024 May;
5(7):1010-1023.
PMID: 38750245
Chimeric antigen receptor (CAR) T cells used for the treatment of B cell malignancies can identify T cell subsets with superior clinical activity. Here, using infusion products of individuals with...
7.
Kumaresan P, Wurster S, Bavisi K, da Silva T, Hauser P, Kinnitt J, et al.
mBio
. 2024 Feb;
15(4):e0341323.
PMID: 38415653
Invasive aspergillosis (IA) is a common and deadly mold infection in immunocompromised patients. As morbidity and mortality of IA are primarily driven by poor immune defense, adjunct immunotherapies, such as...
8.
Kwak L, Szymura S, Wang L, Zhang T, Cha S, Dong Z, et al.
Res Sq
. 2023 Oct;
PMID: 37790486
Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade B-cell lymphoma of the bone marrow. Despite a cumulative risk of progression, there is no approved therapy for patients in the asymptomatic phase....
9.
Wang X, Srour S, Mendoza T, Whisenant M, Subbiah I, Gonzalez E, et al.
Br J Haematol
. 2023 Feb;
201(4):738-746.
PMID: 36733986
This cross-sectional study aimed to develop and validate a patient-reported outcomes (PROs) assessment tool to assess symptom burden and daily functioning in patients after chimeric antigen receptor (CAR) T-cell therapy,...
10.
Westin J, Davis R, Feng L, Hagemeister F, Steiner R, Lee H, et al.
J Clin Oncol
. 2022 Aug;
41(4):745-755.
PMID: 35952327
Purpose: Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib...